Bimatoprost implant (Durysta™), developed by Allergan, is a sustained-release drug delivery system containing bimatoprost, a prostaglandin analogue with ocular hypotensive activity. The implant, administered intracamerally, involves the use of a biodegradable, solid polymer drug delivery system for slow, sustained drug release, designed to lower intraocular pressure (IOP) over a 4- to 6-months period. In March 2020, bimatoprost implant received its first approval, in the USA, for use to reduce IOP in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). Allergan's clinical development programme for bimatoprost implant is ongoing. This article summarizes the milestones in the development of bimatoprost implant leading to this first approval for use in the reduction of IOP in patients with OAG or OHT.

中文翻译：

---

比马前列素植入物：首次批准。


比马前列素植入物 (Durysta™) 由艾尔建 (Allergan) 开发，是一种缓释药物输送系统，含有比马前列素（一种具有降眼压活性的前列腺素类似物）。该植入物通过前房内给药，使用可生物降解的固体聚合物药物输送系统来缓慢、持续地释放药物，旨在在 4 至 6 个月的时间内降低眼内压 (IOP)。 2020 年 3 月，比马前列素植入物在美国首次获得批准，用于降低开角型青光眼 (OAG) 或高眼压症 (OHT) 患者的眼压。艾尔建 (Allergan) 的比马前列素植入物临床开发计划正在进行中。本文总结了比马前列素植入物开发的里程碑，该植入物首次被批准用于降低 OAG 或 OHT 患者的 IOP。